Charles River (NYSE: CRL) interim CFO reports stock award and share move

Rhea-AI Filing Summary

Charles River Laboratories International, Inc. executive Michael Gunnar Knell, CSVP, CAO and Interim CFO, reported equity-related transactions in company common stock. On January 30, 2026, he acquired 1,668 shares at $0 per share, reflecting performance share units earned from awards granted on May 26, 2023.

On the same date, Knell disposed of 526 shares of common stock at $211.68 per share. After these transactions, he directly held 14,602 shares of Charles River Laboratories common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Knell Michael Gunnar

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MA 01887

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSVP, CAO, Interim CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		1,668(1)	A	$0	15,128	D
Common Stock	01/30/2026		F		526	D	$211.68	14,602	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023.

	/s/ Michael G. Knell	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CRL executive Michael Gunnar Knell report?

Michael Gunnar Knell reported acquiring 1,668 Charles River Laboratories common shares at $0 and disposing of 526 shares at $211.68 on January 30, 2026. Following these transactions, he directly held 14,602 CRL common shares.

What is the role of Michael Gunnar Knell at Charles River Laboratories (CRL)?

Michael Gunnar Knell serves as CSVP, Chief Accounting Officer, and Interim Chief Financial Officer of Charles River Laboratories International, Inc. His Form 4 filing reflects changes in his directly held CRL common stock position on January 30, 2026.

How many CRL shares did Michael Gunnar Knell hold after the January 30, 2026 transactions?

After the January 30, 2026 transactions, Michael Gunnar Knell directly held 14,602 shares of Charles River Laboratories common stock. This total reflects both the 1,668-share acquisition and the 526-share disposition reported in the Form 4.

What explains the 1,668 CRL shares acquired by Michael Gunnar Knell?

The 1,668 CRL shares were issued following achievement of performance goals in performance share unit awards originally granted on May 26, 2023. These awards converted into common stock once the specified performance criteria were met.

What do the transaction codes A and F indicate in Knell’s CRL Form 4?

The Form 4 shows code A for the acquisition of 1,668 CRL common shares at $0 and code F for the disposition of 526 shares at $211.68. These codes categorize the nature of each reported equity transaction.